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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Primary antibody deficiency is the most common disorder among
primary immunodeficiencies. Recurrent infection and chronic lung change often lead to
mortality and morbidity.
Methods: This study focused on the clinical presentation, molecular diagnosis, and outcomes
of primary antibody deficiency in Taiwan pediatric group. Medical records of patients with
primary antibody deficiency during the period 1990e2010 were retrospectively reviewed in
one medical center.
Results: Among the 34 patients evaluated, X-linked agammaglobulinemia (XLA) (29.4%) and
common variable immunodeficiency diseases (CVIDs) (29.4%) were the most common disorders
presented with respiratory and skin infections. Some genotype/phenotype discordance was
found in one family. Patients with XLA, CVID, and hyper-IgM syndrome without complications
had higher trough and initial IgG levels, and shorter delays in diagnosis. Patients with trough
IgG levels >700 mg/dL had less occurrence of bronchiectasis.
Conclusion: These results summarized clinical manifestations of primary antibody deficiency in
pediatric group in Taiwan. Clinicians should strive to shorten delays in diagnosis and maintain
higher trough IgG levels to decrease subsequent mortality and morbidity.
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Features of primary antibody deficiency 341Introduction
Primary immunodeficiencies are disorders resulting in
increased susceptibility to uncommon pathogens, and
recurrent and severe infections. Aside from infections,
autoimmune diseases and malignancy might also be
the associated disorders. The wide range of incidence, from
1/500 to 1/500,000, in the general population is due to
a variety of subtypes that cause various symptoms.1,2
Among the heterogeneous groups of primary immunodefi-
ciencies, different incidence reports from different regions
in the world show that antibody deficiencies are the most
frequently diagnosed disorders, ranging from 50% to 70%.3e5
In general, selective immunoglobulin A (IgA) deficiency is
the most frequent primary antibody deficiency but its clin-
ical symptoms are obscure.6 However, the incidence rate of
selective immunoglobulin A (IgA) deficiency varies between
Western and Eastern countries. For example, the prevalence
of selective IgA deficiency is 1:223 to 1:1000 in the USA,7
while it is about 1:3230 in China.8 Selective IgA deficiency
is more common in Caucasians. X-linked agammaglobulin-
emia (XLA) and common variable immunodeficiency diseases
(CVIDs) are the two major groups wherein Ig replacement is
used to prevent complications. Another group of antibody
deficiencies, transient hypogammaglobulinemia of infancy
(THI), is noted in children aged 1e2 years. The disease
course is often benign as serum Ig levels increasewith age. In
Taiwan, one large cohort study has shown that primary
antibody deficiency is the predominant group (36.3%) of
primary immunodeficiency, and recurrent sinopulmonary
infection is the most common presentation.9
Once primary antibody deficiency is diagnosed, intra-
venous immunoglobulin (IVIG) provides an effective treat-
ment to improve survival and prevent infections,10e13 with
earlier institution of IVIG treatment providing better
outcomes. Under regular IVIG replacement, the survival
rate increases to more than 90%.3,9 However, recurrent
infections, bronchiectasis, and impaired lung functions are
still major complications in spite of IVIG replacement, so
many studies have focused on finding optimal serum IgG
levels to prevent complications.
The current study focused on pediatric patients with
primary antibody deficiency in a tertiary center and
recorded initial Ig levels, trough IgG levels, diagnosed ages,
initial presentations, and subsequent symptoms. The study
also aimed at determining the relationship between Ig
levels and outcomes.
Materials and methods
Data collection
The charts of the patients with suspected antibody defi-
ciencies, indicated by the International Classification of
Disease, Ninth Revision (ICD-9), in the Department of
Pediatrics of National Taiwan University Hospital from 1990
to 2010 were screened and retrospectively reviewed. This
study was approved by the institutional review board of
National Taiwan University Hospital. The ICD-9 codes
ranged from 279.00 to 279.09, which represented disorders
of humoral immunity. Initially 232 patients were enrolled,and we excluded those who did not meet the criteria of the
World Health Organization Scientific Group, the Pan-
American Group for Immunodeficiency, and the European
Society for Immunodeficiencies.14,15 Other secondary
immunodeficiencies such as protein-losing enteropathy,
chromosome abnormalities, drug-induced immunodefi-
ciency, and prematurity were also excluded.
We recorded ages of onset, which were defined as the age
at which the first episode of invasive infection or chronic
course of sinusitis and otitismedia occurred. Ages of diagnosis
were also recorded when the final diagnosis was made in our
hospital after a series of workups were done. Diagnosis delay
time was presented as the duration from the time of disease
onset to the timeof diagnosis. Initial and subsequent episodes
of infections of each patient were also recorded. Bacteremia
and central nervous system infection were confirmed by
documented pathogens from blood and cerebrospinal fluid
cultures. Bronchiectasis was diagnosed by chest radiography
and computed tomography. Lung function tests were done by
standard spirometry. Each documented pathogen of infection
was presented to see the specific distribution.
Immunologic studies and molecular analysis
All patients received immunologic tests by standard tech-
niques, including complete blood count with differential
count, serum Ig levels, functional antibody levels, and
lymphocyte subsets by flow cytometry. Mitogen tests for
lymphocyte proliferation assay, CH50, neutrophil oxidative
burst assay, and chemotaxis assay were performed in some
patients to exclude other immunodeficiencies. Bruton
tyrosine kinase (BTK ) genes were analyzed by polymerase
chain reaction-direct sequencing. CD40/CD40 ligand was
analyzed by flow cytometry and genomic DNAs of two
patients were sent to the Queen Mary Hospital in Hong Kong
for CD40 ligand sequencing.
Outcomes
Patients with XLA, CVID, and hyper-immunoglobulin M (IgM)
syndrome were further divided into the complication and the
noncomplication groups based on the subsequent symptoms
and outcomes during follow-up. The complication group
included patients with chronic sinusitis, otitis media, pneu-
monia, invasive bacterial infections, bronchiectasis, impaired
lung function, failure to thrive, malignancy, and autoimmune
diseases, or those with mortality. Patients in the non-
complication group had no other morbidity or severe
infections.
Statistical analysis
Data were expressed as mean  standard deviation for age,
laboratory data, and individual values with percentage for
episodes of symptoms and infections. Data analysis was per-
formed using the computer-based SPSS statistical software
(version 17.0).ManneWhitneyU testwasused tocompare the
diagnosis delay, age of onset, and initial and trough IgG levels
in patients with and without long-term complications.
Fisher’s exact test was used to analyze the relationship
between subsequent symptoms and trough IgG levels.
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Demographic characteristics of primary antibody
deficiencies
Thirty-four patients who met the criteria of primary anti-
body deficiencies for the past 20 years in National Taiwan
University Hospital were recruited. The most frequent
disorders were CVID (10 patients) and XLA (10 patients),
followed by THI (eight patients) and hyper-IgM syndrome
(two patients). One patient had symptomatic selective IgA
deficiency and three had selective IgG3 subclass defi-
ciencies. Male (30 patients) to female (four patients) ratio
was 7.5:1. No antenatal diagnoses were made.
Six patients from four unrelated families had family
histories. Four had a family history of XLA. The other two
patients, one with hyper-IgM syndrome and the other with
XLA, had uncertain early death due to infections in their
family. The age of onset on presentation ranged from 3
months to 9 years, and the age of diagnosis ranged from 4
months to 36 years. The diagnosis delay time varied from
0 to 33 years (Table 1).
Initial presentations and laboratory studies
Recurrent upper respiratory tract infection (15 patients,
44.1%) and recurrent sinopulmonary infection (16 patients,Table 1 Demographic data, initial presentations, and serum Ig
Characteristics CVID
(n Z 10)
XLA
(n Z 10)
Sex
Male 8 10
Female 2 0
Age at onset (mo, mean  SD) 36.6  21.76 31.8  32.21
Age at diagnosis (mo, mean  SD) 54.0  32.9 90.9  126.5
Diagnosis delay (mo, mean  SD) 17.4  36.4 59.1  120.5
Presenting symptoms (n, %)
Frequent URI 4 (40%) 6 (60%)
Sinopulmonary infection 6 (60%) 5 (50%)
Skin infection 1 (10%) 3 (30%)
Gastroenteral infection 2 (20%) 0
Osteomyelitis and arthritis 1 (10%) 3 (30%)
Bacteremia 2 (20%) 3 (30%)
CNS infection 1 (10%) 0
Failure to thrive 0 1 (10%)
Oral thrush 0 0
Laboratory data (mean ± SD)
IgG level(mg/dL) 305.1  181.7 226.9  217.6
IgA level (mg/dL) Undetectable Undetectable
IgM level (mg/dL) 82.1  50.5 22.8  8.5
WBC (K/mL) 8566  2663.1 10,868  4534
Hemoglobin (g/dL) 12.1  1.1 12.9  2.1
Platelet (k/mL) 277.7  97.2 390.9  74
CNS Z central neural system; CVID Z common variable immunodefi
THIZ transient hypogammaglobulinemia of infancy; URIZ upper res
linked agammaglobulinemia.47.1%) were the most common initial presentations. Skin
infections, including cellulitis and recurrent folliculitis,
were the third common manifestation (eight patients,
23.5%). Bacteremia was found only in patients with XLA
and CVID (five patients, 14.7%). Recurrent gastroenteritis
was present in two patients with CVID and one with THI.
Only one patient with CVID initially presented with
central nervous system infection by Acinetobacter bau-
mannii. This patient also developed sepsis. Aside from
infections, failure to thrive was also one of the initial
presentations. There was at least one patient in each
group of XLA, THI, hyper-IgM syndrome, and selective IgA
deficiency (Table 1).
In terms of laboratory data, initial serum IgG levels
were all <350 mg/dL in CVID, XLA, THI, and hyper-IgM
syndrome. Initial serum IgG levels were extremely low
(46.3  7.1 mg/dL), especially in hyper-IgM syndrome.
Serum IgA levels were usually below the detection limit in
patients with XLA, CVID, THI, and selective IgA deficiency.Molecular diagnosis
Fifteen patients from 11 unrelated families received
genetic studies (44.1%), and genetic defects were
found in the BTK genes (nine patients with XLA) and
CD40L genes (one patient with hyper-IgM syndrome)
(Table 2).levels.
THI
(n Z 8)
Hyper-IgM
syndrome
(n Z 2)
Selective
IgA deficiency
(n Z 1)
IgG subclass
deficiency
(n Z 3)
8 2 0 2
0 0 1 1
6.4  3.9 4.5  0.7 49 26.7  23.9
9  4 20.5  21.9 170 40.3  38
2.6  2.6 16  22.6 121 19.7  15.2
1 (12.5%) 1 (50%) 0 3 (100%)
2 (25%) 2 (100%) 1 0
2 (25%) 1 (50%) 1 0
1 (12.5%) 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
1 (12.5%) 1 (50%) 1 0
2 (25%) 0 0 0
288.8  99.6 46.3  7.1 1290 970.5  352.8
Undetectable 5.3  4.2 <10 80  45.2
60.2  29.5 101  55.2 121 118.7  11
8019  2661 15,000  7778 16,880 9183  1583
11.4  1.2 12.4  3.3 10.2 11.5  0.6
441.5  175.3 672.5  74.3 267 437.3  96.6
ciency disease; Ig Z immunoglobulin; SD Z standard deviation;
piratory tract infection; WBCZ white blood cell count; XLAZ X-
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Thirty-two patients were followed up for a mean dura-
tion of 8.0  6.2 years. Two patients’ data were lost to
follow-up, including one with XLA and one with selective
IgA deficiency. One patient with XLA with an initial IgG
level of 164 mg/dL at the age of 14 months was lost to
follow-up after bone marrow examination. A patient
with selective IgA deficiency had serum IgA levels
<10 mg/dL without low serum IgG levels. Recurrent
sinusitis, pneumonia, and failure to thrive were noted
since the age of 4 years. The patient was also lost to
follow-up for several months, so the subsequent course
was not clear.
The overall mortality rate was 12.5%, including patients
with XLA (three) and hyper-IgM syndrome (one). Two
patients with XLA expired due to severe respiratory failure
caused by bronchiectasis, while the other two patients
succumbed to severe septic shock. Severe respiratory
complications, including bronchiectasis and impaired lung
functions, accounted for 21.9%, mostly in patients with
XLA, CVID, and hyper-IgM syndrome.
Failure to thrive was also noted in 15.6% of all patients.
Three more patients (two with CVID and one with XLA) had
failure to thrive on follow-up. All of them were followed up
from childhood to adolescence, and their height and body
weight gradually fell below the third percentile of age. The
other two patients with initial failure to thrive did not catch
up during follow-up.
Half of patients had allergic diseases, and only one,
a patient with CVID, had an autoimmune disease diagnosedTable 2 Molecular findings and phenotypes.
No. Gene cDNA
mutation
Exon Codon
mutation
Domain Initi
leve
(mg
1 Btk c.1713T>G 17 Y571X TK 59
2 Btk c.569delC 7 P190fsX8 TH 3
3 Btk c.862C>T 10 R288 W SH2 232
4 Btk c.862C>T 10 R288 W SH2 718
5 Btk c.1000T>C 12 Y344H SH2 180
6 Btk IVS11þ6T>G 11 Splicing SH2 33
7 Btk Unknown Splicing Unknown 275
8 Btk c.1106 T->C 13 L369P SH2 459
9 CD40L c.476 G->A 5 W140X Intracellular 41
Btk Z Bruton tyrosine kinase; CD40L Z CD40 ligand; Ig Z immunogloas inflammatory bowel disease. There was no malignancy in
this series (Table 3).
Regarding subsequent infections, sinopulmonary infec-
tions were the most common complications. Recurrent
sinusitis was found in 56.3% of all patients, followed by
recurrent pneumonia (25%). Invasive bacteremia accounted
for 18.8% (three XLA patients, one CVID, one hyper-IgM
syndrome, and one IgG subclass deficiency). Documented
infections existed mainly in patients with XLA, CVID, and
hyper-IgM syndrome. The major pathogen in all 50 episodes
of infection was Haemophilus influenza (38%) with the
presentations of pneumonia and sepsis (Table 4). Pseudo-
monas aeruginosa (12%), also found in patients with XLA
and hyper-IgM syndrome, was mainly cultured from sputum
and ear discharge. We also found fungal infections with
Candida albicans from sputum and urine culture, and
Cryptococcus sp. from the culture of skin abscess. One
patient with CVID had herpes zoster infection.
The initial IgG levels, age of diagnosis, diagnosis delay
time, and trough IgG levels between those with severe/
chronic complications and those without were compared.
Patients in the complication group were older and had
longer diagnosis delay time, but not statistically significant
(Fig. 1). After IVIG supplementation, trough IgG levels were
significantly higher in the noncomplication group than in
the complication group (Fig. 2). In XLA, CVID, and hyper-IgM
syndrome patients, incidences of recurrent infections,
bacteremia, and failure to thrive in the group were low,
with trough IgG levels being >700 mg/dL. They also had
significantly less bronchiectasis and impaired lung functions
(p Z 0.041) (Table 5).al IgG
ls
/dL)
B cell (%) Presentation
0 Pneumonia with pleural effusion, otitis
media, parasinusitis, failure to thrive,
bronchiectasis, Haemophilus sepsis
0.2 Arthritis, repeated pneumonia,
Haemophilus sepsis, positive family
history, bronchiectasis
0.6 P. aeruginosa sepsis, oral ulcer, twin A
0.4 P. aeruginosa septic shock, oral ulcer,
twin B
1 Pneumonia, urinary tract infection
with vesicoureteral reflux Grade III,
positive family history
.1 1 Frequent upper respiratory tract
infection and pneumonia
0 Anal fistula, repeated pneumonia,
bronchiectasis
0.14 Frequent upper respiratory tract
infection without severe infections,
strong family history, mild bronchiectasis
.2 26.65 Pneumococcal pneumonia with
pleural effusion and frequent otitis
media, bronchiectasis
bulin.
Table 3 Subsequent symptoms, outcomes, and trough IgG levels.
Characteristics CVID
(n Z 10)
XLA (n Z 9) THI (n Z 8) Hyper-IgM
syndrome
(n Z 2)
IgG subclass
deficiency
(n Z 3)
Total (n Z 32)
Follow-up years (mean  SD) 9.8  5.8 10.9  6.2 2.8  1.4 11.3  4.7 5.6  8.2 8.0  6.2
IVIG use (n, %) 10 (100%) 8 (88.9%) 2 (25%) 2 (100%) 2 (66.7%) 24 (75%)
Trough IgG level (mean  SD) 671.1  161.2 666.7  146.4 673.4  191.1 442  103.7 993.7  402.6 656.3  169.9
Follow-up symptoms (n, %)
Recurrent otitis media 1 (10%) 2 (22.2%) 1 (12.5%) 0 0 4 (12.5%)
Recurrent sinusitis 7 (70%) 8 (88.9%) 1 (12.5%) 1 (50%) 1 (33.3%) 18 (56.3%)
Recurrent pneumonia 2 (20%) 4 (44.4%) 0 1 (50%) 1 (33.3%) 8 (25%)
Recurrent gastroenteritis 3 (30%) 1 (11.1%) 0 1 (50%) 0 5 (15.6%)
Recurrent UTI 0 0 0 0 0 0
Recurrent skin infection 1 (10%) 2 (22.2%) 0 0 0 3 (9.4%)
Recurrent arthritis 0 1 (11.1%) 0 0 0 1 (3.1%)
Bacteremia 1 (10%) 3 (33.3%) 0 1 (50%) 1 (33.3%) 6 (18.8%)
CNS infection 0 0 0 0 0 0
Bronchiectasis 2 (20%) 4 (44.4%) 0 1 (50%) 0 7 (21.9%)
Impaired lung function 2 (20%) 4 (44.4%) 0 1 (50%) 0 7 (21.9%)
Allergy 7 (70%) 0 4 (50%) 0 1 (33.3%) 16 (50%)
Autoimmune disease 1 (10%) 0 0 0 0 1 (3.1%)
Malignancy 0 0 0 0 0 0
Failure to thrive 2 (20%) 2 (22.2%) 0 1 (50%) 0 5 (15.6%)
Death 0 3 (33.3%) 0 1 (50%) 0 4 (12.5%)
CNS Z central nervous system; CVID Z common variable immunodeficiency disease; Ig Z immunoglobulin; IVIG Z intravenous
immunoglobulin; THI Z transient hypogammaglobulinemia of infancy; UTI Z urinary tract infection; XLA Z X-linked agammaglobu-
linemia.
Table 4 Documented pathogen and hypogammaglobulinemia.
Pathogen CVID XLA THI Hyper-IgM
syndrome
IgG subclass
deficiency
Total
Bacteria
Campylobacter coli 0 1 (2.8%) 0 0 0 1
Escherichia coli 2 (28.6%) 0 0 0 0 2
Enterobacter 0 1 (2.8%) 0 0 0 1
Enterococcus sp. 0 1 (2.8%) 0 0 0 1
H. influenza 0 18 (50%) 0 1 (16.7%) 0 19
Klebsiella sp. 0 3 (8.3%) 0 0 0 3
Moraxella sp. 0 1 (2.8%) 0 0 0 1
Staphylococcus aureus 0 3 (8.3%) 0 0 0 3
Pantoea agglomerans 0 1 (2.8%) 0 0 0 1
S. pneumoniae 2 (28.6%) 1 (2.8%) 0 1 (16.7%) 1 5
Proteus sp. 0 1 (2.8%) 0 0 0 1
P. aeruginosa 0 3 (8.3%) 0 3 (50%) 0 6
Salmonella sp. 1 (14.3%) 1 (2.8%) 0 0 0 2
Virus
Herpes zoster 1 (14.3%) 0 0 0 0 1
Fungus
Candida sp. 0 1 (2.8%) 0 1 (16.7%) 0 2
Cryptococcus neoformans 1 (14.3%) 0 0 0 0 1
Total episodes 7 36 0 6 1 50
CVID Z common variable immunodeficiency disease; Ig Z immunoglobulin; THI Z transient hypogammaglobulinemia of infancy;
XLA Z X-linked agammaglobulinemia.
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Figure 1 The ages at onset, ages upon diagnosis, and diag-
nosis delay time (in months) for patients with XLA, CVID, and
hyper-IgM syndrome, who were divided into the non-
complication and complication groups. Values were presented
as mean  SD. Ages upon diagnosis and diagnosis delay time
were higher in the complication group than in the non-
complication group, but without any significant difference.
CVID Z common variable immunodeficiency disease;
Ig Z immunoglobulin; SD Z standard deviation; XLA Z
X-linked agammaglobulinemia.
Features of primary antibody deficiency 345Ig replacement therapy
Twenty-four (75%) patients received regular IVIG treatment
with a dose interval of 400e 800 mg/kg every 3e4 weeks,
according to infection status and trough IgG levels, and most
had CVID, XLA, and hyper-IgM syndrome. Two patients with
THI and two with IgG subclass deficiencies also received IVIG
temporally due to frequent episodes of infections. They had
reduced episodes of infections after IVIG treatment. Mean
trough IgG levels increased to >660 mg/dL in all groups with
initially low serum IgG levels. However, two patients with
hyper-IgM syndrome still had low serum IgG levels (average,
442  103.7 mg/dL) despite regular IVIG replacement
therapy every 3e4 weeks (Table 4).Figure 2 The initial and trough serum IgG levels for patients
with XLA, CVID, and hyper-IgM syndrome. Values were pre-
sented as mean  SD. Serum IgG levels increased significantly
in both groups after IVIG replacement therapy. Trough IgG
levels were significantly lower in the complication group than
in the noncomplication group (p Z 0.041). CVID Z common
variable immunodeficiency disease; Ig Z immunoglobulin;
IVIGZ intravenous immunoglobulin; SDZ standard deviation;
XLA Z X-linked agammaglobulinemia.Discussion
The current study focuses on the disease course of primary
antibody deficiency in a tertiary center in Taiwan and shows
that CVID and XLA are the most common disorders, similar
to the findings of other studies in Taiwan,9,16 Singapore,
and other registries from Norway and Ireland.17e20 Male
predominance, with male:female ratio of 7.5:1, is very
significant, as in previous reports. In contrast, some studies
show that specific antibody deficiencies, including those of
IgG subclass or selective IgA deficiency, are the predomi-
nant disorders.3,4,21 In Taiwan’s pediatric groups, serum
IgG/A/M and IgG subclass levels are checked for recurrent
or invasive infections. Symptoms of selective IgA deficiency
are usually subclinical, so it is often underestimated. In the
current study, only one patient has been found with
selective IgA deficiency due to recurrent infections and
failure to thrive, which raises the clinicians’ awareness
regarding checking of serum Ig levels.
Molecular diagnosis was performed for patients with
suspected XLA and hyper-IgM syndrome. Most patients with
BTK gene mutation were compatible with their typical
presentations and B-cell percentages. Interestingly, among
them two were identical twins who shared the same BTK
gene mutation and initial presentations (No. 3 and 4 in
Table 2). However, twin B had nearly normal serum IgG
levels (initial IgG levels: 718 mg/dL) upon diagnosis, unlike
his twin A brother (initial IgG levels: 232 mg/dL). This
difference of initial IgG levels in the same genetic back-
ground might have been caused by the differences in
disease status of initial Pseudomonas infection and in
nutritional status, which might have affected the catabo-
lism of IgG. In addition to the external factors, there still
were possibilities of a second mutation existing in an
upstream or intron regulatory region of the btk gene
between these twin brothers. On the other hand, other
known or unknown regulatory factors might affect the
translation of btk genes. Discordant phenotypes with varied
serum IgG levels in affected family members with same btk
mutation were also reported previously.22,23 Another recent
study on 62 Chinese XLA patients by Lee et al24 supported
the genotype/phenotype correlations of XLA in ChineseTable 5 Relationship between trough IgG levels and
following symptoms.
Symptoms Trough IgG level p
700e
(n Z 13)
700þ
(n Z 8)
Recurrent otitis media 2 (15.4%) 3 (37.5%) 0.325
Recurrent sinusitis 10 (76.9%) 6 (75%) 1
Recurrent pneumonia 6 (46.1%) 1 (12.5%) 0.174
Recurrent gastroenteritis 4 (30.7%) 1 (12.5%) 0.36
Recurrent skin infection 2 (15.4%) 1 (12.5%) 1
Bacteremia 5 (38.5%) 0 0.111
Bronchiectasis 7 (53.8%) 0 0.018*
Impaired lung function 7 (53.8%) 0 0.018*
Failure to thrive 5 (38.5%) 0 0.111
Frequent admission 6 (46.1%) 2 (25%) 0.4
* p < 0.05 between the two groups.
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members of the same family had been documented.
Graziani et al25 and Conley et al26 reported atypical
presentations of XLA. In the current study, one patient (No.
8 in Table 2) with XLA mutation had a strong family history
of early infant death and low circulating B cells with
borderline low serum IgG levels. The patient only had a past
history of frequent upper respiratory infections without any
invasive infections or hospitalization, and was not diag-
nosed until the age of 35 years. During follow-up, chest
computed tomography revealed that the patient had mild
bronchiectasis. Although there are genotype/phenotype
correlations in XLA,24,27,28 discordant findings under the
same background of genetic mutation or atypical presen-
tations point to some epigenetic change or other regulatory
factors that may influence the XLA phenotype.
In this cohort, recurrent sinopulmonary infections and
bacteremia are the most common presentations in patients
with primary antibody deficiencies, consistent with
previous studies. In addition, skin infection is the third most
common initial manifestations (23.5% of all patients). These
skin infections include recurrent folliculitis and cellulitis.
One patient even had prolonged varicella infection. Skin
infections accounted for 15.5% of antibody deficiencies in
a previous study in Taiwan9 and 8.3% in a report on Thai
children.3 The recurrent skin infection may be one of the
common presentations of antibody deficiencies, although
skin infections are often associated with other cellular or
well-defined immunodeficiencies.
Despite the high frequency of IVIG supplementation,
recurrent sinopulmonary and airway infections are still the
most frequent complications in patients with CVID, XLA,
and hyper-IgM syndrome. H. influenza plays major roles in
respiratory tract infections in the current study. This is
also consistent with a previous report,29 but its definite
role in pneumonia is still in question because it is also
a normal flora of the respiratory tract. In fact, Strepto-
coccus pneumoniae is the most common pathogen of
community-acquired pneumonia in Taiwan, and H. influ-
enza accounts only for 4.8e9%.30,31 The study of infections
in CVID patients in France also supports this distribution of
pathogens of pneumonia.32 However, H. influenza is still
the cause of most sepsis cases in the current study, while
P. aeruginosa is the major pathogen of sepsis in other
studies.3,16
In addition to bacterial infections, viral and fungal
infections are rare, as found in previous reports.9,.29,32 Most
patients have the ability to recover from these infections
due to the normal T-cell responses. In the current study,
only one patient suffered from herpes zoster infection, two
from Candida infections, and one from Cryptococcus
infection. Complaints about frequent upper respiratory
tract infection and sinusitis were very common during
follow-up, but examinations of respiratory specimens were
not performed. A recent study of 12 adult patients with
hypogammaglobulinemia suggested that rhinovirus might
cause prolonged and frequent respiratory tract infec-
tions.33 Viruses may not be a major cause of severe
mortality and morbidity, but their influence on chronic
inflammation of the respiratory tract may be a factor in
chronic lung changes. The role of viral infection warrants
further investigation.Patients with CVID, XLA, and hyper-IgM syndrome were
further divided into two groups depending on the occur-
rence of recurrent or long-term complications. Initial and
trough IgG levels were lower in the complication group.
Delayed time of diagnosis was also longer in patients with
complications, but without statistical significance. This is
the first study focusing on the relationship between serum
IgG levels and complications in Taiwan. The reason why
serum trough IgG levels were not increased accordingly in
complication group might be the different catabolisms of
IgG under IVIG supplement. The patients’ nutritional
status, gastrointestinal losses, or numbers of infection
during follow-up might affect the catabolism of IgG levels.
Clinically, we need to further re-evaluate the patients’
infection status, nutrition, and psychosocial conditions if
the efficacy of IVIG is not satisfactory. However, the limi-
tation exists in too few populations of these patients, and
cross-area database should be established in the future to
clarify the factors that influence the outcomes. With
improved knowledge and awareness of immunodeficiency,
delays in diagnosis decreases gradually,3,34 leading to
greater survival and outcomes.35 On the other hand, initial
serum IgG levels, upon diagnosis, may influence the disease
course of the current study, even though few reports have
focused on this issue.
One recent multicenter prospective cohort study in the
Italian Primary Immunodeficiency Network (IPINET) data-
base showed a higher risk of pneumonia in CVID patients
with low basal IgG levels, IgA levels, and trough IgG
levels.36 In an in vitro mitogenic stimulation study, Ig
secretion from B cells in pediatric patients with hypogam-
maglobulinemia was much lower than that of normal pop-
ulations, even after the clinical Ig levels were corrected.37
Lower initial IgG levels, along with delayed diagnosis, may
cause patients to be more susceptible to infections and
lead to some irreversible pulmonary destruction prior to
IVIG replacement therapy. However, this hypothesis
requires large and strict studies to be validated.
The trough IgG levels >700 mg/dL in patients can reduce
the occurrence of bronchiectasis or chronic lung change
significantly. Early and prolonged IVIG replacement thera-
pies can improve the outcome of primary hypogamma-
globulinemia,13 shorten hospitalization,38 and lessen
pneumonia episodes.36,39,40 Many studies are further
focusing on the optimal serum IgG levels to prevent
complications after IVIG replacement therapy. A random-
ized, double-blinded crossover trial in 43 patients with
primary hypogammaglobulinemia further indicates that
high-dose IVIG is associated with a significant reduction in
complications of infection.41 The overall consensus among
clinical immunologists is to maintain serum IgG levels
>500 mg/dL,13,42,43 and set even higher IgG levels of
>800 mg/dL to prevent bronchiectasis.13 Another meta-
analysis suggests that aggressive IVIG replacement that
increases trough IgG levels up to 1000 mg/dL can reduce
the risk of pneumonia.39
In contrast, a multicenter prospective cohort study in
the IPINET database has shown no significant difference in
the trough IgG levels between patients with and those
without bronchiectasis.36 It also shows that pneumonia is
a risk factor for bronchiectasis and vice versa. The definite
mechanism of IVIG in protecting against chronic lung
Features of primary antibody deficiency 347change remains inconclusive. According to the results here
and in previous studies, higher trough IgG levels may
prevent chronic lung damage by reducing the episodes
of pulmonary infection, so the vicious cycle can be
broken. However, since the results remain controversial,
there may not be an absolute cutoff value of trough
IgG levels for all patients. Regular IVIG replacement
remains beneficial in all patients with primary hypogam-
maglobulinemia. Further, we assume that clinical symp-
toms signify whether they are sufficient or not, and
suggest that the dosage of IVIG should be individualized to
keep patients symptom free.References
1. De Vries E. Patient-centred screening for primary immunode-
ficiency: a multi-stage diagnostic protocol designed for non-
immunologists. Clin Exp Immunol 2006;145:204e14.
2. Stiehm ER, Ochs HD, Winkelstein JA. Immunodeficiency disor-
ders: general consideration. In: Stiehm ER, editor. Immuno-
logic disorders in infants and children. 5th ed. Philadelphia:
Saunders; 2004. p. 289e355.
3. Benjasupattananan P, Simasathein T, Vichyanond P,
Leungwedchakarn V, Visitsunthorn N, Pacharn P, et al. Clinical
characteristics and outcomes of primary immunodeficiencies in
Thai children: an 18-year experience from a tertiary care
center. J Clin Immunol 2009;29:357e64.
4. Javier III FC, Moore CM, Sorensen RU. Distribution of primary
immunodeficiency diseases diagnosed in a pediatric tertiary
hospital. Ann Allergy Asthma Immunol 2000;84:25e30.
5. Onigbanjo MT, Orange JS, Perez EE, Sullivan KE. Hypogamma-
globulinemia in a pediatric tertiary care setting. Clin Immunol
2007;125:52e9.
6. Yel L. Selective IgA deficiency. J Clin Immunol 2010;30:10e6.
7. Cunningham-Rundles C. Physiology of IgA and IgA deficiency. J
Clin Immunol 2001;21:303e9.
8. Feng ML, Zhao YL, Shen T, Huang H, Yin B, Liu RZ, et al.
Prevalence of immunoglobulin A deficiency in Chinese blood
donors and evaluation of anaphylactic transfusion reaction
risk. Transfus Med 2011;21:338e43.
9. Lee W-I, Jaing T-H, Hsieh M-Y, Kuo M-L, Lin S-J, Huang J-L.
Distribution, infections, treatments and molecular analysis in
a large cohort of patients with primary immunodeficiency
diseases (PIDs) in Taiwan. J Clin Immunol 2006;26:274e83.
10. Roifman CM, Gelfand EW. Replacement therapy with high dose
intravenous gamma-globulin improves chronic sinopulmonary
disease in patients with hypogammaglobulinemia. Pediatr
Infect Dis J 1988;7(5 Suppl.):S92e6.
11. Buckley RH, Schiff RI. The use of intravenous immune globulin
in immunodeficiency diseases. N Engl J Med 1991;325:110e7.
12. Liese JG, Wintergerst U, Tympner KD, Belohradsky BH. High- vs
low-dose immunoglobulin therapy in the long-term treatment
of X-linked agammaglobulinemia. Am J Dis Child 1992;146:
335e9.
13. Quartier P, Debre M, De Blic J, de Sauverzac R, Sayegh N,
Jabado N, et al. Early and prolonged intravenous immuno-
globulin replacement therapy in childhood agammaglobulin-
emia: a retrospective survey of 31 patients. J Pediatr 1999;
134:589e96.
14. Primary immunodeficiency diseases. Report of a WHO scientific
group. Clin Exp Immunol 1997;109(Suppl. 1):1e28.
15. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for
primary immunodeficiencies. Representing PAGID (Pan-Amer-
ican Group for Immunodeficiency) and ESID (European Society
for Immunodeficiencies). Clin Immunol 1999;93:190e7.16. Lee WI, Kuo ML, Huang JL, Lin SJ, Wu CJ. Distribution and
clinical aspects of primary immunodeficiencies in a Taiwan
pediatric tertiary hospital during a 20-year period. J Clin
Immunol 2005;25:162e73.
17. Stray-Pedersen A, Abrahamsen TG, Froland SS. Primary
immunodeficiency diseases in Norway. J Clin Immunol 2000;
20:477e85.
18. Lim DL, Thong BY, Ho SY, Shek LP, Lou J, Leong KP, et al.
Primary immunodeficiency diseases in Singaporedthe last 11
years. Singapore Med J 2003;44:579e86.
19. Abuzakouk M, Feighery C. Primary immunodeficiency disorders
in the Republic of Ireland: first report of the national registry in
children and adults. J Clin Immunol 2005;25:73e7.
20. Lee PP, Lau YL. Primary immunodeficiencies: "new" disease in
an old country. Cell Mol Immunol 2009;6:397e406.
21. Baumgart KW, Britton WJ, Kemp A, French M, Roberton D. The
spectrum of primary immunodeficiency disorders in Australia. J
Allergy Clin Immunol 1997;100:415e23.
22. Morwood K, Bourne H, Gold M, Gillis D, Benson EM. Phenotypic
variability: clinical presentation between the 6th year and the
60th year in a family with X-linked agammaglobulinemia. J
Allergy Clin Immunol 2004;113:783e5.
23. Bykowsky MJ, Haire RN, Ohta Y, Tang H, Sung SS, Veksler ES,
et al. Discordant phenotype in siblings with X-linked agam-
maglobulinemia. Am J Hum Genet 1996;58:477e83.
24. Lee PP, Chen TX, Jiang LP, Chan KW, Yang W, Lee BW, et al.
Clinical characteristics and genotype-phenotype correlation in
62 patients with X-linked agammaglobulinemia. J Clin Immunol
2010;30:121e31.
25. Graziani S, Di Matteo G, Benini L, Di Cesare S, Chiriaco M,
Chini L, et al. Identification of a Btk mutation in a dysgamma-
globulinemic patient with reduced B cells: XLA diagnosis or
not? Clin Immunol 2008;128:322e8.
26. Conley ME, Farmer DM, Dobbs AK, Howard V, Aiba Y,
Shurtleff SA, et al. A minimally hypomorphic mutation in Btk
resulting in reduced B cell numbers but no clinical disease. Clin
Exp Immunol 2008;152:39e44.
27. Plebani A. Clinical, immunological, and molecular analysis in
a large cohort of patients with X-linked agammaglobulinemia:
an Italian multicenter study. Clin Immunol 2002;104:221e30.
28. Broides A, Yang W, Conley M. Genotype/phenotype correla-
tions in X-linked agammaglobulinemia. Clin Immunol 2006;
118:195e200.
29. Chang SH, Yang YH, Chiang BL. Infectious pathogens in pedi-
atric patients with primary immunodeficiencies. J Microbiol
Immunol Infect 2006;39:503e15.
30. Lauderdale TL, Chang FY, Ben RJ, Yin HC, Ni YH, Tsai JW, et al.
Etiology of community acquired pneumonia among adult
patients requiring hospitalization in Taiwan. Respir Med 2005;
99:1079e86.
31. Yen MY, Hu BS, Chen YS, Lee SS, Lin YS, Wann SR, et al. A
prospective etiologic study of community-acquired pneumonia
in Taiwan. J Formos Med Assoc 2005;104:724e30.
32. Oksenhendler E, Gerard L, Fieschi C, Malphettes M, Mouillot G,
Jaussaud R, et al. Infections in 252 patients with common
variable immunodeficiency. Clin Infect Dis 2008;46:1547e54.
33. Kainulainen L, Vuorinen T, Rantakokko-Jalava K, O¨sterback R,
Ruuskanen O. Recurrent and persistent respiratory tract viral
infections in patients with primary hypogammaglobulinemia. J
Allergy Clin Immunol 2010;126:120e6.
34. Rezaei N, Aghamohammadi A, Moin M, Pourpak Z, Movahedi M,
Gharagozlou M, et al. Frequency and clinical manifestations of
patients with primary immunodeficiency disorders in Iran:
update from the Iranian Primary Immunodeficiency Registry. J
Clin Immunol 2006;26:519e32.
35. Champi C. Primary immunodeficiency disorders in children:
prompt diagnosis can lead to lifesaving treatment. J Pediatr
Health Care 2002;16:16e21.
348 H.-Y. Chan et al.36. Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G,
Agostini C, et al. Effectiveness of immunoglobulin replacement
therapy on clinical outcome in patients with primary antibody
deficiencies: results from a multicenter prospective cohort
study. J Clin Immunol 2011;31:315e22.
37. Kidon MI, Handzel ZT, Schwartz R, Altboum I, Stein M, Zan-
Bar I. Symptomatic hypogammaglobulinemia in infancy and
childhooddclinical outcome and in vitro immune responses.
BMC Fam Pract 2004;5:23, Published online 2004 October 21.
doi:10.1186/1471-2296-5-23.
38. Bayrakci B, Ersoy F, Sanal O, Kilic S, Metin A, Tezcan I. The
efficacy of immunoglobulin replacement therapy in the long-
term follow-up of the B-cell deficiencies (XLA, HIM, CVID).
Turk J Pediatr 2005;47:239e46.
39. Orange JS, GrossmanWJ, Navickis RJ,WilkesMM. Impact of trough
IgG on pneumonia incidence in primary immunodeficiency:
ameta-analysis of clinical studies.Clin Immunol 2010;137:21e30.40. Pourpak Z, Aghamohammadi A, Sedighipour L, Farhoudi A,
Movahedi M, Gharagozlou M, et al. Effect of regular intrave-
nous immunoglobulin therapy on prevention of pneumonia in
patients with common variable immunodeficiency. J Microbiol
Immunol Infect 2006;39:114e20.
41. Eijkhout HW, van Der Meer JW, Kallenberg CG,
Weening RS, van Dissel JT, Sanders LA, et al. The effect of
two different dosages of intravenous immunoglobulin on
the incidence of recurrent infections in patients with
primary hypogammaglobulinemia. A randomized, double-
blind, multicenter crossover trial. Ann Intern Med 2001;
135:165e74.
42. Furst DE. Serum immunoglobulins and risk of infection: how
low can you go? Semin Arthritis Rheum 2009;39:18e29.
43. Ballow M, Notarangelo L, Grimbacher B, Cunningham-
Rundles C, Stein M, Helbert M, et al. Immunodeficiencies. Clin
Exp Immunol 2009;158:14e22.
